Other Information.
−Removed: 3.1 Articles of Incorporation of Registra nt , as amended (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K filed on March 22, 2024)
+Added: Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements
+Added: During the three months ended June 30, 2024, neither the Company or any of its officers or directors adopted or terminated trading arrangements for the sale of the Company’s common stock .
+Added: 3.1 Articles of Incorporation of Registrant, as amended (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K filed on March 22, 2024)
3.2 Amended and Restated Bylaws of Registrant (incorporated by reference to Exhibit 3.2 to our Annual Report on Form 10-K filed on March 2, 2021)
−Removed: Form of Pre-Funded Warrant (incorp orated by reference to Exhibit 4.1 to our Curr ent Report on Form 8-K filed on January 29, 2024)
−Removed: A mendmen t to Common Stock Purchase Warrants (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on March 13, 2024)
−Removed: Form of Securities Purchase Agreement, dated as of January 29, 2024, by and among Skye Bioscience, Inc.
−Removed: and the Investors named therein
−Removed: Form of Registration Rights Agreement, dated as of January 29 , 20 24 , by and among Skye Bioscience, Inc.
−Removed: and the Investors named therein (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on January 29, 2024)
−Removed: Form of Securities Purchase Agreement, dated as of March 11, 2024, by and among Skye Bioscience, Inc.
−Removed: and the Investors named therein (incorporated by reference to Exhibit 10.
−Removed: 1 to our Current Report on Form 8-K filed on March 13 , 2024)
−Removed: Form of Registration R ights Agreement, dated as of March 11, 2024, by and among Skye Bioscience, Inc.
−Removed: and the Investors named therein (incorporated by reference to Exhibit 10.
−Removed: 2 to our Current Report on Form 8-K filed on March 13, 2024)
+Added: 2024 Inducement Equity Incentive Plan
+Added: Form of Stock Option Grant Notice and Stock Option Agreement under the 2024 Inducement Equity Incentive Plan
+Added: Form of Restricted Stock Unit Award Grant Notice and Restricted St ock Unit Award Agreement under the 2024 Inducement Equity Incentive Plan
+Added: Equity Distribution Agreement, dated as of May 10, 2024, by and between Skye Bioscience, Inc.
+Added: and Piper Sandler & Co.
+Added: (incorporated by reference to Exhibit 1.2 to our Registration Statement on Form S-3 filed May 10, 2024)
31.1* Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
14 unchanged sentences
a Nevada corporation
−Removed: May 10, 2024 By:
+Added: August 9, 2024 By:
/s/ Punit Dhillon
2 unchanged sentences
(Principal Executive Officer)
−Removed: May 10, 2024 By:
+Added: August 9, 2024 By:
/s/ Kaitlyn Arsenault
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.